Ocular Oncology and Pathology

Singaravelu J. · Melendez-Moreno A. · Wrenn J. · Singh A.D.

Author affiliations

Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: November 23, 2022
Accepted: December 26, 2022
Published online: January 13, 2023

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2

ISSN: 2296-4681 (Print)
eISSN: 2296-4657 (Online)

For additional information: https://www.karger.com/OOP

Abstract

Introduction: Determining the nature of iris melanocytic tumors based on clinical exam alone remains challenging. Tumor-associated vasculature of iris melanocytic lesions may facilitate the ability to discern between iris nevus and melanoma. Methods: In a single-institution, retrospective, observational study of 45 patients with pathologically confirmed iris melanoma and 15 patients with iris nevi that were either clinically stable or pathologically confirmed were included. Tumor characteristics and associated vasculature were identified on clinical exam and slit-lamp photographs. Fluorescein angiographic parameters including feeder vessels, intrinsic vessels, leakage, masking, and angiographic silence were assessed. Results: Feeder vessels were present in 17 (43%) melanomas and were absent in the nevus group (p = 0.002). Thirty-three (83%) iris melanomas and 5 (33%) iris nevi were observed to have intrinsic vessels, and a statistically significant association of intrinsic vessels with malignancy (p = 0.001) was noted. Fluorescein leakage was also observed more frequently in iris melanoma 39 (98%) than in nevi 9 (60) with a significant difference (p = 0.001). Angiographic silence occurred in 3 nevi (20%) and was not observed in any melanoma (p = 0.017). Overall, the presence of intrinsic vessels +/− feeder vessels had high sensitivity (0.85) and high positive predictive value (0.87) for diagnosis of iris melanoma. Conclusions: Anterior segment fluorescein angiography allows for the assessment of tumor-associated vascular patterns and demonstrates utility in differentiating iris nevi from melanoma. Feeder vessels were only observed in iris melanoma and were absent in iris nevi. The intrinsic vessels were present more frequently in melanomas and are thus associated with malignancy. Angiographic silence is indicative of iris nevi.

© 2023 S. Karger AG, Basel

References Damato B, Singh AD; Ohio Library and Information Network. Clinical ophthalmic oncology: uveal tumors. Cham, Switzerland: Springer; 2019. Harbour JW, Augsburger JJ, Eagle RC Jr. Initial management and follow-up of melanocytic iris tumors. Ophthalmology. 1995 Dec;102(12):1987–93. Arentsen JJ, Green WR. Melanoma of the iris: report of 72 cases treated surgically. Ophthalmic Surg. 1975;6(2):23–37. Shields JA, Sanborn GE, Augsburger JJ. The differential diagnosis of malignant melanoma of the iris. A clinical study of 200 patients. Ophthalmology. 1983 Jun;90(6):716–20. Zimmerman LE. Clinical Pathology of Iris tumors. Am J Ophthalmol. 1963 Aug;56:183–95. Kersten RC, Tse DT, Anderson R. Iris melanoma. Nevus or malignancy? Surv Ophthalmol. 1985 May-Jun;29(6):423–33. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989 May 4;339(6219):58–61. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020 May;77(9):1745–70. Dart JK, Marsh RJ, Garner A, Cooling RJ. Fluorescein angiography of anterior uveal melanocytic tumours. Br J Ophthalmol. 1988 May;72(5):326–37. Hodes BL, Gildenhar M, Choromokos E. Fluorescein angiography in pigmented iris tumors. Arch Ophthalmol. 1979 Jun;97(6):1086–8. Jakobiec FA, Depot MJ, Henkind P, Spencer WH. Fluorescein angiographic patterns of iris melanocytic tumors. Arch Ophthalmol. 1982 Aug;100(8):1288–99. Demeler U. Fluorescence angiographical studies in the diagnosis and follow-up of tumors of the iris and ciliary body. Adv Ophthalmol. 1981;42:1–17. Brovkina AF, Chichua AG. Value of fluorescein iridography in diagnosis of tumours of the iridociliary zone. Br J Ophthalmol. 1979 Mar;63(3):157–60. Bandello F, Brancato R, Lattanzio R, Carnevalini A, Rossi A, Coscas G. Biomicroscopy and fluorescein angiography of pigmented iris tumors. A retrospective study on 44 cases. Int Ophthalmol. 1994;18(2):61–70. Jakobiec FA, Silbert G. Are most iris “melanomas” really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol. 1981 Dec;99(12):2117–32. Jakobiec FA, Coleman DJ, Chattock A, Smith M. Ultrasonically guided needle biopsy and cytologic diagnosis of solid intraocular tumors. Ophthalmology. 1979 Sep;86(9):1662–81. Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, de Keizer RJ, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012 Jan;130(1):57–64. Conway RM, Chua WC, Qureshi C, Billson FA. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol. 2001 Jul;85(7):848–54. Skalet AH, Li Y, Lu CD, Jia Y, Lee B, Husvogt L, et al. Optical coherence tomography angiography characteristics of Iris melanocytic tumors. Ophthalmology. 2017 Feb;124(2):197–204. Kottow M. Fluorescein angiographic behaviour of iris masses. Ophthalmologica. 1977;174(4):217–23. Geisse LJ, Robertson DM. Iris melanomas. Am J Ophthalmol. 1985 Jun;99(6):638–48. Cheng H, Bron AJ, Easty D. A study of iris masses by fluorescein angiography. Trans Ophthalmol Soc U K. 1971;91:199–205. McLean IW, Zimmerman LE, Evans RM. Reappraisal of callender’s spindle a type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol. 1978 Oct;86(4):557–64. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of callender’s classification of uveal melanoma at the armed forces institute of pathology. Am J Ophthalmol. 2018 Nov;195:lvi–lx. Article / Publication Details

First-Page Preview

Received: November 23, 2022
Accepted: December 26, 2022
Published online: January 13, 2023

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2

ISSN: 2296-4681 (Print)
eISSN: 2296-4657 (Online)

For additional information: https://www.karger.com/OOP

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.